A biopharmaceutical startup led by the former CEO of one Jacksonville's fastest-growing companies debuted on the Nasdaq stock exchange on Friday, priced at $5 a share.
The drug being developed by Cadrenal is an oral anti-coagulant that Pham has previously said could replace warfarin as a standard medication. The company is looking to sell 1.4 million shares of stock, raising $7 million before expenses. Various existing shareholders, including the Boys & Girls Club of Northeast Florida, are expected to sell another 1.7 million shares.
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
출처: JaxBizJournal - 🏆 599. / 51 더 많은 것을 읽으십시오 »
출처: KRLD - 🏆 75. / 68 더 많은 것을 읽으십시오 »
출처: JaxBizJournal - 🏆 599. / 51 더 많은 것을 읽으십시오 »